THE DISCONNECT BETWEEN FUNDING DECISIONS OF CANCER DRUGS AND COMPANION DIAGNOSTIC TESTS IN CANADA
Author(s)
Poinas A, Wyatt G
Wyatt Health Management, Oakville, ON, Canada
Presentation Documents
More and more pharmaceuticals receive indications that require the use of companion diagnostic tests to identify subgroups of patients who would benefit from the therapy. Many mutations have been identified in cancer and the choice of treatment frequently depends on the result of a specific companion diagnostic test. In Canada, the pan Canadian Oncology Drug Review (pCODR) assesses cancer drugs based on clinical evidence, cost-effectiveness and patient input, to make recommendations to Canada’s provinces in guiding their funding decisions.The objective of this study is to determine how pCODR assesses drugs that require a companion diagnostic. METHODS: All pCODR recommendations as of were reviewed and those involving the use of a companion diagnostic were identified. Analysis of these recommendations was conducted to determine how companion diagnostic tests accompanying cancer drugs were reviewed by pCODR. RESULTS: pCODR has received 52 submissions since its inception and 39 recommendations have been issued. Of these recommendations, 9 involved the use of a companion diagnostic test. Both positive and negative comments around companion diagnostic tests were found among the pCODR recommendations. (Results will be tabulated) CONCLUSIONS: pCODR recommendations are dedicated to cancer drugs. However for those drugs requiring a companion diagnostic, pCODR also looks at the information related to these tests, e.g. costs and utility. However, there is no submission process for companion diagnostic tests at pCODR. Consequently, there is opportunity for inconsistency among the pCODR recommendations for cancer drugs and associated companion diagnostic tests.
Conference/Value in Health Info
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCN134
Topic
Epidemiology & Public Health, Health Policy & Regulatory, Organizational Practices
Topic Subcategory
Academic & Educational, Disease Classification & Coding, Pricing Policy & Schemes
Disease
Oncology